Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.02/06/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Australia Health | Brain | Brain Cancers | Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Neurology | Renal Cell Carcinoma | Study | Urology & Nephrology